JP2018527335A - 癌の治療に対するラパマイシン及びラパマイシン誘導体の安定なリポソーム製剤 - Google Patents

癌の治療に対するラパマイシン及びラパマイシン誘導体の安定なリポソーム製剤 Download PDF

Info

Publication number
JP2018527335A
JP2018527335A JP2018506339A JP2018506339A JP2018527335A JP 2018527335 A JP2018527335 A JP 2018527335A JP 2018506339 A JP2018506339 A JP 2018506339A JP 2018506339 A JP2018506339 A JP 2018506339A JP 2018527335 A JP2018527335 A JP 2018527335A
Authority
JP
Japan
Prior art keywords
drug
liposome
umirolimus
liposomes
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018506339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527335A5 (enExample
Inventor
ティン−ビン ユー
ティン−ビン ユー
ジーウェイ シー
ジーウェイ シー
シー−ホン スー
シー−ホン スー
Original Assignee
マンリ インターナショナル リミテッド
マンリ インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンリ インターナショナル リミテッド, マンリ インターナショナル リミテッド filed Critical マンリ インターナショナル リミテッド
Publication of JP2018527335A publication Critical patent/JP2018527335A/ja
Publication of JP2018527335A5 publication Critical patent/JP2018527335A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018506339A 2015-09-09 2015-09-21 癌の治療に対するラパマイシン及びラパマイシン誘導体の安定なリポソーム製剤 Pending JP2018527335A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/849,100 2015-09-09
US14/849,100 US20170065520A1 (en) 2015-09-09 2015-09-09 Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer
PCT/US2015/051206 WO2017044135A1 (en) 2015-09-09 2015-09-21 Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer

Publications (2)

Publication Number Publication Date
JP2018527335A true JP2018527335A (ja) 2018-09-20
JP2018527335A5 JP2018527335A5 (enExample) 2018-11-01

Family

ID=58189920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506339A Pending JP2018527335A (ja) 2015-09-09 2015-09-21 癌の治療に対するラパマイシン及びラパマイシン誘導体の安定なリポソーム製剤

Country Status (6)

Country Link
US (1) US20170065520A1 (enExample)
EP (1) EP3346989B1 (enExample)
JP (1) JP2018527335A (enExample)
CN (1) CN108024962A (enExample)
ES (1) ES2849730T3 (enExample)
WO (1) WO2017044135A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023163355A (ja) * 2022-04-28 2023-11-10 プレシエンス バイオテクノロジー インコーポレイテッド ラパマイシンまたはその誘導体を含むリポソーム、およびそれらの治療における使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
IT202000007228A1 (it) * 2020-04-06 2021-10-06 Diego Dolcetta SOMMINISTRAZIONE DI INIBITORI DI mTOR NEL SISTEMA NERVOSO CENTRALE
US12433874B2 (en) 2022-04-28 2025-10-07 Prescience Biotechnology Inc. Liposome comprising rapamycin or a derivative thereof and use thereof in therapy
CN117159724B (zh) * 2023-04-04 2024-07-05 上海交通大学医学院附属仁济医院 一种脂质体-dna水凝胶复合给药系统及其制备方法
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500836A (ja) * 2007-10-23 2011-01-06 トランセーブ， インコーポレイテッド リポソーム化バンコマイシン製剤
WO2013176223A1 (ja) * 2012-05-23 2013-11-28 国立大学法人大阪大学 炎症性疾患治療用医薬組成物
JP2014111596A (ja) * 2012-12-03 2014-06-19 Manli International Ltd 癌を処置するためのウミロリムスおよびその誘導体の使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
WO1998017256A1 (en) * 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US20110244028A1 (en) * 2008-09-26 2011-10-06 Steve Leigh Method of solubilizing biologically active compounds
US20130337051A1 (en) * 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
KR102310786B1 (ko) * 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
WO2015068020A2 (en) * 2013-11-05 2015-05-14 García-Sánchez Gustavo A Immunosuppressive treatments, formulations and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500836A (ja) * 2007-10-23 2011-01-06 トランセーブ， インコーポレイテッド リポソーム化バンコマイシン製剤
WO2013176223A1 (ja) * 2012-05-23 2013-11-28 国立大学法人大阪大学 炎症性疾患治療用医薬組成物
JP2014111596A (ja) * 2012-12-03 2014-06-19 Manli International Ltd 癌を処置するためのウミロリムスおよびその誘導体の使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023163355A (ja) * 2022-04-28 2023-11-10 プレシエンス バイオテクノロジー インコーポレイテッド ラパマイシンまたはその誘導体を含むリポソーム、およびそれらの治療における使用

Also Published As

Publication number Publication date
CN108024962A (zh) 2018-05-11
US20170065520A1 (en) 2017-03-09
WO2017044135A1 (en) 2017-03-16
EP3346989A4 (en) 2019-05-08
ES2849730T3 (es) 2021-08-20
EP3346989A1 (en) 2018-07-18
EP3346989B1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
EP3346989B1 (en) Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer
US11446247B2 (en) Liposome composition and pharmaceutical composition
CN1960729B (zh) 伊立替康制剂
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
KR102653436B1 (ko) 암의 치료에서 사용하기 위한 리포솜 제형
ES2984148T3 (es) Medicamento de combinación que contiene una composición liposómica que encapsula un fármaco y un inhibidor de punto de control inmunitario
WO2004017943A2 (en) Non-vesicular cationic lipid formulations
US20240216528A1 (en) Application of pharmaceutical composition having specific drug-to-lipid ratio in antitumor
Mahmood et al. Engineered liposomal nanoparticles and their medical applications
JP2020079303A (ja) リポソーム及びリポソーム組成物
HK40045737A (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
JPWO2009125858A1 (ja) ２−インドリノン誘導体を含有する脂質分散体製剤
HK40041777A (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
HK40041777B (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200128